PSA velocity and doubling time in diagnosis and prognosis of prostate cancer

British Journal of Medical and Surgical Urology

Volumn 5, Issue 4, 2012, Pages 162-168

  Vickers, Andrew J ^a   Brewster, Simon F ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Prostate specific antigen; Prostatic neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ALGORITHM; ANTIGEN DETECTION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; MATHEMATICAL ANALYSIS; MEDICAL HISTORY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RECURRENCE RISK; REVIEW; VELOCITY;

EID: 84861974848     PISSN: 18759742     EISSN: 18759750     Source Type: Journal    
DOI: 10.1016/j.bjmsu.2011.08.006     Document Type: Review

References (35)

1. O'Brien M.F., Cronin A.M., Fearn P.A., Smith B., Stasi J., Guillonneau B., et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009, 27:3591-3597.
2. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006, 98:529-534.
3. Vickers A.J., Till C., Tangen C.M., Lilja H., Thompson I.M. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011, 103:462-469.
4. Carter H.B., Kettermann A., Ferrucci L., Landis P., Metter E.J. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 2007, 70:685-690.
5. Kettermann A.E., Ferrucci L., Trock B.J., Metter E.J., Loeb S., Carter H.B. Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer. BJU Int 2010, 106:1284-1290. [discussion 90-2].
6. D'Amico A.V., Hanks G.E. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993, 72:2638-2643.
7. D'Amico A.V., Cote K., Loffredo M., Renshaw A.A., Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002, 20:4567-4573.
8. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
9. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007, 25:1765-1771.
10. Dotan Z.A., Bianco F.J., Rabbani F., Eastham J.A., Fearn P., Scher H.I., et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005, 23:1962-1968.
11. Stephenson A.J., Scardino P.T., Kattan M.W., Pisansky T.M., Slawin K.M., Klein E.A., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007, 25:2035-2041.
12. Moul J.W., Wu H., Sun L., McLeod D.G., Amling C., Donahue T., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004, 171:1141-1147.
13. Oudard S., Banu E., Scotte F., Banu A., Medioni J., Beuzeboc P., et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007, 18:1828-1833.
14. Semeniuk R.C., Venner P.M., North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006, 68:565-569.
15. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C., de Wit R., Tannock I.F., Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007, 13:6396-6403.
16. Carter H.B., Ferrucci L., Kettermann A., Landis P., Wright E.J., Epstein J.I., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006, 98:1521-1527.
17. Loeb S., Roehl K.A., Catalona W.J., Nadler R.B. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 2007, 177:899-902.
18. Khatami A., Aus G., Damber J.E., Lilja H., Lodding P., Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007, 120:170-174.
19. van den Bergh R.C., Roemeling S., Roobol M.J., Wolters T., Schroder F.H., Bangma C.H. Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer-a review. Eur Urol 2008, 54:505-516.
20. Palma D., Tyldesley S., Blood P., Liu M., Morris J., Pickles T. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. Int J Radiat Oncol Biol Phys 2007, 67:1425-1429.
21. D'Amico A.V., Chen M.H., Roehl K.A., Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, 351:125-135.
22. NCCN Clinical Practice Guidelines in Oncology Prostate cancer early detection 2010 February, National Comprehensive Cancer Network, Available from: URL:. http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf.
23. Carter H.B., Pearson J.D., Metter E.J., Brant L.J., Chan D.W., Andres R., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992, 267:2215-2220.
24. Ulmert D., Serio A.M., O'Brien M.F., Becker C., Eastham J.A., Scardino P.T., et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008, 26:835-841.
25. Vickers A.J., Wolters T., Savage C.J., Cronin A.M., O'Brien M.F., Roobol M.J., et al. Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy. J Urol 2010, 184:907-912.
26. Stephenson A.J., Scardino P.T., Eastham J.A., Bianco F.J., Dotan Z.A., Fearn P.A., et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006, 98:715-717.
27. Eggener S.E., Scardino P.T., Walsh P.C., Han M., Partin A.W., Trock B.J., et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011, 185:869-875.
28. Kattan M.W., Cuzick J., Fisher G., Berney D.M., Oliver T., Foster C.S., et al. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 2008, 112:69-74.
29. Vickers A.J., Cronin A.M., Bjork T., Manjer J., Nilsson P.M., Dahlin A., et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010, 341:c4521.
30. Vickers A.J., Wolters T., Savage C.J., Cronin A.M., O'Brien M.F., Pettersson K., et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol 2009, 56:753-760.
31. D'Amico A.V., Renshaw A.A., Sussman B., Chen M.H. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005, 294:440-447.
32. Stephenson A.J., Kattan M.W., Eastham J.A., Bianco F.J., Yossepowitch O., Vickers A.J., et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009, 27:4300-4305.
33. Ross A.E., Loeb S., Landis P., Partin A.W., Epstein J.I., Kettermann A., et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010, 28:2810-2816.
34. Fall K., Garmo H., Andren O., Bill-Axelson A., Adolfsson J., Adami H.O., et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007, 99:526-532.
35. O'Brien M.F., Cronin A.M., Fearn P.A., Savage C.J., Smith B., Stasi J., et al. Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. Int J Cancer 2011, 128:2373-2381.